Search results for "Metastatic"

showing 10 items of 267 documents

The oral KIF11 inhibitor 4SC‐205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma …

2021

Inhibidor de KIF11; Terapias dirigidas; Metástasis Inhibidor de KIF11; Teràpies dirigides; Metàstasi KIF11 inhibitor; Targeted therapies; Metastasis In summary, our study provides a rationale for the future therapeutic integration in clinical trials of 4SC-205, an structurally distinct oral KIF11 inhibitor that shows potent antitumor activity in multiple preclinical neuroblastoma models and sensitizes neuroblastoma cells to standard chemotherapy and specific neuroblastoma-targeted therapies. The financial support for this research was provided by Instituto de Salud Calos III (PI20/00530 to Miguel F. Segura; PI20/01107 to Rosa Noguera; PI17/02248 and CPII18/00027 to Anna Santamaria; PI19/013…

Medicine (General)Neuroblastoma - Tractament:neoplasias::neoplasias por tipo histológico::neoplasias de células germinales y embrionarias::tumores neuroectodérmicos::neoplasias neuroepiteliales::tumores neuroectodérmicos primitivos::tumores neuroectodérmicos primitivos periféricos::neuroblastoma [ENFERMEDADES]Metastatic neuroblastomaMedicació oralMedicaments antineoplàstics - Ús terapèutic:Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]Medicine (miscellaneous)Administration OralKinesinsAntineoplastic Agents:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Letter to Editor:Neoplasms::Neoplasms by Histologic Type::Neoplasms Germ Cell and Embryonal::Neuroectodermal Tumors::Neoplasms Neuroepithelial::Neuroectodermal Tumors Primitive::Neuroectodermal Tumors Primitive Peripheral::Neuroblastoma [DISEASES]MiceNeuroblastomaR5-920Cell Line Tumor:terapéutica::farmacoterapia::vías de administración de medicamentos::administración oral [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]MedicineAnimalsHumansAntitumor activityPrimary (chemistry)business.industry:acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS]Disease Models Animal:Therapeutics::Drug Therapy::Drug Administration Routes::Administration Oral [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]Cancer researchMolecular Medicine:Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [CHEMICALS AND DRUGS]businessClinical and Translational Medicine
researchProduct

Unusual case of dorsal vertebral metastases from a male breast cancer

2017

Introduction: Breast cancer is a malignant neoplasm arising from mammary glands and is a rare entity in the male patient. Spine is a common site for skeletal metastases. Case presentation: A 53-years-old male was admitted to our Neurosurgical unit because of an untreatable dorsal pain. He had been treated 3 years before for breast cancer. A dorsal Magnetic Resonance Imaging (MRI) evidenced pathological masses at T8 level. A total body Computed Tomography (CT) scan revealed lungs and liver metastases. After a multidisciplinary consult, a posterior T8 decompression, a radiofrequency thermoablation in T8 vertebral body followed by screws and rods fixation (T7-T9) was performed. Post-operative …

Medicine (all)Dorsal vertebral metastaticDorsal vertebral metastatic; Male breast cancer; Metastatic breast cancer; Surgery; Therapy; Medicine (all)SurgeryTherapyMetastatic breast cancerMale breast cancer
researchProduct

MBCL-07. NON-METASTATIC MEDULLOBLASTOMA OF EARLY CHILDHOOD: RESULTS FROM THE PROSPECTIVE CLINICAL TRIAL HIT-2000 AND AN EXTENDED VALIDATION COHORT

2020

Abstract OBJECTIVE To avoid craniospinal irradiation (CSI) in children younger than four years with non-metastatic medulloblastoma by chemotherapy, intraventricular methotrexate and risk-adapted local radiotherapy. PATIENTS AND METHODS Eighty-seven patients received systemic chemotherapy and intraventricular methotrexate. Until 2006, CSI was reserved for non-response or progression. After 2006, local radiotherapy was introduced for non-responders or classic (CMB), anaplastic or large-cell medulloblastoma (LCA). Infantile SHH-activated medulloblastomas (SHH_INF) were subdivided by DNA-methylation profiling. Survival in SHH_INF subtypes were also assessed in a validation cohort (n=71). RESULT…

MedulloblastomaOncologyCancer Researchmedicine.medical_specialtybusiness.industrymedicine.disease3. Good healthClinical trialOncologyInternal medicinemedicineNon metastaticMedulloblastoma (Clinical)AcademicSubjects/MED00300AcademicSubjects/MED00310Neurology (clinical)Early childhoodbusinessValidation cohortNeuro-Oncology
researchProduct

Characterization of Human γδ T Lymphocytes Infiltrating Primary Malignant Melanomas

2012

T lymphocytes are often induced naturally in melanoma patients and infiltrate tumors. Given that gamma delta T cells mediate antigen-specific killing of tumor cells, we studied the representation and the in vitro cytokine production and cytotoxic activity of tumor infiltrating gamma delta T cells from 74 patients with primary melanoma. We found that gamma delta T cells represent the major lymphocyte population infiltrating melanoma, and both V delta 1(+) and V delta 2(+) cells are involved. The majority of melanoma-infiltrating gamma delta cells showed effector memory and terminally-differentiated phenotypes and, accordingly, polyclonal gamma delta T cell lines obtained from tumor-infiltrat…

MelanomasCytotoxicity ImmunologicMaleRENAL-CELL CARCINOMA OVERCOMING IMMUNOLOGICAL-TOLERANCE METASTATIC MELANOMA TUMOR-CELLS PHASE-I MEVALONATE PATHWAY TARGETING CTLA-4 LYMPH-NODES IMMUNOTHERAPY CANCERAnatomy and PhysiologySkin NeoplasmsTUMOR-CELLSLymphocytemedicine.medical_treatmentT-LymphocytesSettore MED/19 - Chirurgia PlasticaTARGETING CTLA-4Interleukin 21T-Lymphocyte SubsetsImmune PhysiologyMETASTATIC MELANOMACytotoxic T cellIL-2 receptorSkin TumorsMelanomaOVERCOMING IMMUNOLOGICAL-TOLERANCEAged 80 and overMultidisciplinaryT CellsMelanomaMalignant MelanomaQRReceptors Antigen T-Cell gamma-deltaMiddle AgedCANCERPHASE-Imedicine.anatomical_structureCytokinePhenotypeOncologyCytokinesMedicineFemaleResearch ArticleTumor ImmunologyAdultScienceT cellImmune CellsImmunologyMalignant Skin NeoplasmsDermatologyBiologyImmunophenotypingImmune systemLymphocytes Tumor-InfiltratingmedicineHumansIMMUNOTHERAPYBiologyAgedNeoplasm StagingSettore MED/04 - Patologia GeneraleLYMPH-NODESCancers and NeoplasmsImmunologic Subspecialtiesmedicine.diseaseImmune SystemImmunologyOVERCOMING IMMUNOLOGICAL-TOLERANCE; METASTATIC MELANOMA; TUMOR-CELLS; PHASE-I; MEVALONATE PATHWAY; TARGETING CTLA-4; LYMPH-NODES; IMMUNOTHERAPY; CANCERClinical ImmunologyImmunologic MemoryMEVALONATE PATHWAYPLoS ONE
researchProduct

Combination chemotherapy with mitomycin C, vindesine and melphalan for refractory metastatic breast cancer.

1991

A combination of mitomycin C, vindesine and melphalan was administered to 33 patients with heavily pretreated refractory breast cancer. The overall response rate was 27% with a mean duration of more than 10.2 months. A stabilization with a mean duration of 5.1 months was seen in 56% of cases, while 20% of patients progressed. Gastrointestinal toxicity, mostly grade 1 or 2 nausea/vomiting was seen in 85% of cases, grade 1 or 2 leukopenia in 60% of patients, and grade 1 or 2 thrombocytopenia in 42%. Considering the good compliance of this regimen and the poor prognosis of patients with refractory advanced breast cancer, this combination can be useful as a palliative treatment of breast carcin…

MelphalanOncologyAdultCancer Researchmedicine.medical_specialtyVindesinemedicine.medical_treatmentMitomycinBreast NeoplasmsMitomycinsBreast cancerInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansNeoplasm MetastasisMelphalanAgedChemotherapybusiness.industryMitomycin CPalliative CareCancerCombination chemotherapyGeneral MedicineMiddle Agedmedicine.diseaseMetastatic breast cancerOncologyVindesineFemalebusinessmedicine.drugJournal of cancer research and clinical oncology
researchProduct

Immunocytochemical typification of mesothelial cells in effusions: in vivo and in vitro models.

1994

We have performed immunocytochemical, immunoelectron microscopy, Western blot, and culture techniques using monoclonal antibodies against cytokeratin, vimentin, and desmin on 17 benign and 20 malignant effusions of pleural and ascitic origin. Triple coexpression of these three antigens was observed in benign reactive mesothelial cells as well as in one case of mesothelioma. All metastatic adenocarcinoma cells were consistently negative to desmin and positive to cytokeratin and vimentin. Present results were helpful to distinguish reactive and malignant mesothelioma from metastatic carcinoma cells in effusions.

MesotheliomaPathologymedicine.medical_specialtyHistologyImmunoelectron microscopyBlotting WesternVimentinmacromolecular substancesBiologyAdenocarcinomaModels BiologicalEpitheliumPathology and Forensic MedicineMetastatic carcinomaDesminDiagnosis DifferentialImmunoenzyme TechniquesPleural diseaseCytokeratinmedicineAscitic FluidHumansVimentinCells CulturedGeneral Medicinemedicine.diseasePleural Effusionbiology.proteinAdenocarcinomaKeratinsDesminFemaleMesothelial CellFollow-Up StudiesDiagnostic cytopathology
researchProduct

Non‐bacterial thrombotic endocarditis in a patient with pancreatic carcinoma

2021

Nonbacterial thrombotic endocarditis (NBTE) is a rare condition that most often accompanies a malignant disease and involves a hypercoagulable state. We report the incidental finding of a rare case of an NBTE affecting the tricuspid valve in a patient with metastatic pancreatic carcinoma complicated by severe venous and arterial thromboembolisms.

Metastatic Pancreatic Carcinomamedicine.medical_specialtyTricuspid valvebusiness.industrymedicine.diseaseNonbacterial thrombotic endocarditisGastroenterologyMalignant diseasemedicine.anatomical_structureInternal medicineRare caseMedicineEndocarditisRadiology Nuclear Medicine and imagingPancreatic carcinomaCardiology and Cardiovascular MedicinebusinessEchocardiography
researchProduct

A progressive stage IIIB melanoma treated with oncolytic ECHO-7 virus: A case report

2020

Melanoma is an aggressive skin cancer form with a grave prognosis. Current results suggest that oncolytic virus treatment of melanoma has a high therapeutic potential. ECHO-7 (Rigvir) is the first oncolytic virus registered in Latvia. A female patient was diagnosed with stage IIIB melanoma in December 2012, over 9.4 years ago. After the first excision and re-excision, the patient had several recurrences and disease progressions. After the patient had received surgical treatment in 2014, ECHO-7 virus oncolytic virotherapy was started. Since then, the patient has experienced only one more disease progression episode in May 2015 and has been stable for over 60 months. The patient has not rece…

Metastatic melanomaRigvirCase ReportVirus03 medical and health sciences0302 clinical medicinemelanomamedicineVirotherapyoncolytic virus030304 developmental biologylcsh:R5-9200303 health sciencesbusiness.industryMelanomaGeneral MedicineStage iiibmedicine.diseaseOncolytic virus030220 oncology & carcinogenesisCancer researchvirotherapySkin cancerlcsh:Medicine (General)businessECHO-7metastatic melanomaSAGE Open Medical Case Reports
researchProduct

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?

2019

Background: The immune response in melanoma patients is locally affected by presence of tumor-infiltrating lymphocytes (TILs), generally divided into brisk, nonbrisk, and absent. Several studies have shown that a greater presence of TILs, especially brisk, in primary melanoma is associated with a better prognosis and higher survival rate. Patients and Methods: We investigated by enzyme-linked immunosorbent assay (ELISA) the correlation between PD-1 levels in plasma and the presence/absence of TILs in 28 patients with metastatic melanoma. Results: Low plasma PD-1 levels were correlated with brisk TILs in primary melanoma, whereas intermediate values correlated with the nonbrisk TILs, and hig…

Metastatic melanoma[SDV]Life Sciences [q-bio]plasma PD-1chemical and pharmacologic phenomena[SDV.BC]Life Sciences [q-bio]/Cellular Biologylcsh:RC254-282immune response03 medical and health sciences0302 clinical medicineImmune systembrisk TILmelanomaMedicineIn patientOriginal Researchplasma PD-L1030304 developmental biology0303 health sciencesTumor-infiltrating lymphocytesbusiness.industryMelanomahemic and immune systemslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseasebrisk TILs3. Good healthOncologytumor-infiltrating lymphocytes030220 oncology & carcinogenesisCancer researchbusinesshuman activitiesTherapeutic Advances in Medical Oncology
researchProduct

Breast and chest wall metastatic seeding of adenocarcinoma of the colon with bone metaplasia: immunohistochemical study and differential diagnosis

2011

Metastatic tumorChest wallBone metaplasia
researchProduct